 |
245 Diseases |  |
389 Trials |
|
389 Trials |  |
11400 News |  |
| «12...5556575859606162636465...143144» |
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal, IO biomarker: Photoimmunotherapy with cetuximab-conjugated gold nanorods reduces drug resistance in triple negative breast cancer spheroids with enhanced infiltration of tumor-associated macrophages. (Pubmed Central) - Jul 9, 2021
By enhancing ROS generation, CTX-AuNR plus NIR irradiation reprogrammed TAM polarization to the M1 anti-tumor phenotype, as indicated by macrophage mannose receptor (MMR) downregulation. Thus, CTX-AuNR plus NIR can serve as a potent PIT strategy for treating EGFR-overexpressing TNBC cells.
- ||| olomorasib (LY3537982) / Eli Lilly
New P1 trial, Metastases: KEYNOTE E27: Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) (clinicaltrials.gov) - Jul 8, 2021
P1a/1b, N=260, Not yet recruiting, Sponsor: Eli Lilly and Company
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal: A case of unexpected peripherally inserted central catheter removal from a colorectal cancer patient with cetuximab-induced skin toxicity and contact dermatitis at the peripherally inserted central catheter insertion site: Should we recommend the patient to choose subcutaneous port preferentially? (Pubmed Central) - Jul 7, 2021
We suggest that metastatic colorectal cancer patients treated with cetuximab should be recommended to choose subcutaneous port preferentially to avoid potential risk of unexpected peripherally inserted central catheter removal due to cetuximab-induced skin toxicity or contact dermatitis. Further clinical practices and researches are needed for more profound evidences for better practical suggestions.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
Clinical, P2 data, Journal: Efficacy and safety of topical benzoyl peroxide for prolonged acneiform eruptions induced by cetuximab and panitumumab: A multicenter, phase II trial. (Pubmed Central) - Jul 7, 2021
No patient experienced severe adverse events. Overall, topical benzoyl peroxide may be effective for treating and managing prolonged acneiform eruptions induced by epidermal growth factor receptor inhibitors.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal, Checkpoint inhibition: Safety and Efficacy of Cetuximab-Based Salvage Chemotherapy After Checkpoint Inhibitors in Head and Neck Cancer. (Pubmed Central) - Jul 7, 2021
In most patients, SCAI consisted of weekly, well-tolerated regimens. These observations have implications for current practice due to the limited evidence to date in SCCHN and the scant therapeutic options in this disease, and invite to elucidate which may be the best treatment sequence for head and neck cancer patients in the IO era.
- | ficlatuzumab (AV-299) / LG Chem, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion date, Trial primary completion date, Metastases: P30CA023074: Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Jul 6, 2021
P2, N=74, Active, not recruiting, Sponsor: University of Arizona
These observations have implications for current practice due to the limited evidence to date in SCCHN and the scant therapeutic options in this disease, and invite to elucidate which may be the best treatment sequence for head and neck cancer patients in the IO era. Trial completion date: May 2021 --> Dec 2021 | Trial primary completion date: May 2021 --> Dec 2021
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: A novel strategy for glioblastoma treatment combining alpha-cyano-4-hydroxycinnamic acid with cetuximab using nanotechnology-based delivery systems. (Pubmed Central) - Jul 4, 2021
In conclusion, developed nanostructured delivery systems exhibited a set of favorable attributes and potential to be applied as a promising new alternative for GBM treatment. Graphical abstract .
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono, Opdivo (nivolumab) / Ono Pharma, BMS
Review, Journal: Oral mucositis. Is it present in the immunotherapy of the immune checkpoint pd1/pd-l1 against oral cancer? A systematic review. (Pubmed Central) - Jul 4, 2021
The prevalence of oral mucositis is lower in new immunotherapy with monoclonal antibodies against oral cancer than drugs used so far (chemotherapy drugs [methotrexate, cisplatin] as well as cetuximab). However, more studies should be carried out to confirm these data.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Combination of Epithelial Growth Factor Receptor Blockers and CDK4/6 Inhibitor for Nasopharyngeal Carcinoma Treatment. (Pubmed Central) - Jul 4, 2021
However, more studies should be carried out to confirm these data. Our results provide encouraging preliminary data related to the combination treatment of EGFRi and palbociclib in patients with NPC.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Cav1/EREG/YAP Axis in the Treatment Resistance of Cav1-Expressing Head and Neck Squamous Cell Carcinoma. (Pubmed Central) - Jul 4, 2021
The EGFR-targeting antibody cetuximab (CTX) combined with radiotherapy is the only targeted therapy that has been proven effective for the treatment of locally advanced head and neck squamous cell carcinoma (LA-HNSCC)...Patients whose tumors overexpressed Cav1 experienced regional recurrence a few years after adjuvant radiotherapy ± chemotherapy. Together, our observations suggest that a high expression of Cav1 might be predictive of locoregional relapse of LA-HNSCC.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal: High-Density of FcγRIIIA (CD16) Tumor-Associated Neutrophils in Metastases Improves the Therapeutic Response of Cetuximab in Metastatic Colorectal Cancer Patients, Independently of the HLA-E/CD94-NKG2A Axis. (Pubmed Central) - Jul 3, 2021
Altogether, these results strongly support the use of bispecific antibodies directed against both EGFR and FcγRIIIA (CD16) in mCRC patients, to boost cetuximab-mediated ADCC in RAS wild-type mCRC patients. The preferential overexpression of HLA-E/β2m in metastases, associated with CD94 TILs and responsible for a poor prognosis, provides convincing arguments to inhibit this new immune checkpoint with monalizumab, a humanized anti-NKG2A antibody, in combination with anti- FcγRIIIA/EGFR bispecific antibodies as a promising therapeutic perspective in RAS wild-type mCRC patients.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Activation of epidermal growth factor receptor signaling mediates cellular senescence induced by certain pro-inflammatory cytokines. (Pubmed Central) - Jul 3, 2021
In summary, we report that certain pro-inflammatory cytokines induce cellular senescence through activation of the EGFR-Ras signaling pathway. Our study thus offers new insight into a long-ignored mechanism by which EGFR could regulate cellular senescence and suggests that growth signals themselves may catalyze aging under certain conditions.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal: Survival outcomes in locally advanced cutaneous squamous cell carcinoma presenting with clinical perineural invasion alone. (Pubmed Central) - Jul 3, 2021
They can successfully be treated with chemoradiotherapy. However, many patients still suffer from locoregional recurrences.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion date, Trial primary completion date, Metastases: Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Jul 2, 2021
P2, N=128, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
However, many patients still suffer from locoregional recurrences. Trial completion date: Jul 2020 --> Aug 2022 | Trial primary completion date: Jul 2020 --> Aug 2021
- ||||||| Imjudo (tremelimumab) / AstraZeneca, Pfizer, Imfinzi (durvalumab) / AstraZeneca
Trial completion, Combination therapy, Metastases: KESTREL: Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer (clinicaltrials.gov) - Jul 2, 2021
P3, N=823, Completed, Sponsor: AstraZeneca
Trial completion date: Jul 2020 --> Aug 2022 | Trial primary completion date: Jul 2020 --> Aug 2021 Active, not recruiting --> Completed
- || Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal: Evaluation of RAS mutational status through BEAMing assay to monitor disease progression of metastatic colorectal cancer: a case report. (Pubmed Central) - Jul 1, 2021
Then, the patient consecutively received FOLFOX bevacizumab, TAS-102, regorafenib and FOLFIRI followed by de Gramont maintenance treatment...The longitudinal assessment of RAS status offers considerable advantages in order to avoid side effects and economic costs for ineffective treatment choices. Liquid biopsy could help better monitor the disease and provide molecularly guided treatments.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Preclinical, Journal: Formulation and in vivo efficacy study of cetuximab decorated targeted bioadhesive nanomedicine for non-small-cell lung cancer therapy. (Pubmed Central) - Jul 1, 2021
These results demonstrate the therapeutic potential of the prepared nanoformulation. After proper clinical validation, it could be a promising approach for the treatment of NSCLC.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Interesting that KRAS inhibition May theoretically increase Cetuximab synergy. @pashtoonkasi (Twitter) - Jun 30, 2021
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Neoplastic meningitis due to colorectal cancer. (Pubmed Central) - Jun 30, 2021
The progression of neoplastic meningitis is fast and it has a poor prognosis. Diagnosis in the early stages is important to prevent progression of neurological symptoms and to provide the most effective treatment.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Outcome of colorectal cancer in Diamond-Blackfan syndrome with a ribosomal protein S19 mutation. (Pubmed Central) - Jun 30, 2021
He received 5FU and cetuximab; however, his anemia made chemotherapy difficult, and he did not survive long. Patients with Diamond-Blackfan anemia should be screened earlier and more often for colorectal cancer than usual.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal, PD(L)-1 Biomarker, IO biomarker: Tumor-Specific Antibody, Cetuximab, Enhances the In Situ Vaccine Effect of Radiation in Immunologically Cold Head and Neck Squamous Cell Carcinoma. (Pubmed Central) - Jun 30, 2021
These findings suggest an opportunity to improve the treatment of HNSCC by combining radiation and cetuximab to engage an innate anti-tumor immune response that may prime an effective adaptive immune response when combined with immune checkpoint blockade. It is possible that this approach could be extended to any immunologically cold tumor that does not respond to immune checkpoint blockade alone and for which a tumor-specific antibody exists or could be developed.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] COST ANALYSIS OF TOPIC INTERVENTIONS AND QUALITY OF LIFE RELATED TO RADIATION DERMATITIS: EORTC QLQ-C30; QLQ-H&N43 AND SKINDEX 29 OUTCOMES. () - Jun 29, 2021 - Abstract #MASCCISOO2021MASCC_ISOO_440;
Conclusions Advanced wound care was cost-effective from our preliminary analysis. The possibility to reduce skin toxicity with IMRT and topical intervention evidenced the efficacy to reduce interruption of RT and an improvement of QoL.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Montelukast-Based Premedication Regimen for Recurrent Cetuximab Infusion-Related Reactions. (Pubmed Central) - Jun 26, 2021
The possibility to reduce skin toxicity with IMRT and topical intervention evidenced the efficacy to reduce interruption of RT and an improvement of QoL. No abstract available
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono, Herceptin (trastuzumab) / Roche
Clinical, P2 data, Journal: Phase II study evaluating the association of gemcitabine, trastuzumab and erlotinib as first-line treatment in patients with metastatic pancreatic adenocarcinoma (GATE 1). (Pubmed Central) - Jun 26, 2021
This triplet combination is effective in terms of disease control, PFS and OS, and acceptable for safety. A larger study to investigate this combination compared to the standard regimen should be discussed.
- ||| Keytruda (pembrolizumab) / Merck (MSD)
Trial completion, IO biomarker, Metastases: Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055) (clinicaltrials.gov) - Jun 25, 2021
P2, N=172, Completed, Sponsor: Merck Sharp & Dohme Corp.
A larger study to investigate this combination compared to the standard regimen should be discussed. Active, not recruiting --> Completed
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Cancer cell-specific protein delivery by optoporation with laser-irradiated gold nanorods. (Pubmed Central) - Jun 24, 2021
GNRs were labeled with the anti-EGFR (epidermal growth factor receptor) antibody Erbitux to target human ovarian carcinoma cells OVCAR-3...As a result of the irradiation, the uptake of an anti-Ki-67 antibody was observed in about 50 % of the cells. The results of fluorescence lifetime imaging show that the GNR detached from the membrane after irradiation.
- | Keytruda (pembrolizumab) / Merck (MSD), Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal, HEOR: Pembrolizumab alone or with chemotherapy for squamous cell carcinoma of the head and neck: A cost-effectiveness analysis from Chinese perspective. (Pubmed Central) - Jun 24, 2021
For HNSCC patients with different CPS, pembrolizumab alone was the optimal choice for total population and patients with CPS ≥ 1. Among patients with high CPS, immunotherapy with or without chemotherapy was not preferred over the standard therapy.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Review, Journal, Monotherapy: Cetuximab monotherapy for relapsing high-grade mucoepidermoid carcinoma: A case report and review of the literature. (Pubmed Central) - Jun 24, 2021
Among patients with high CPS, immunotherapy with or without chemotherapy was not preferred over the standard therapy. No abstract available
- ||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Herceptin (trastuzumab) / Roche
Clinical, Journal, Adverse events: Dermatological Side Effects of Targeted Antineoplastic Therapies: A Prospective Study. (Pubmed Central) - Jun 24, 2021
Forty-two patients were using trastuzumab (single therapy in 29 patients and combined therapy in 13 patients), five patients were using cetuximab, three patients were using sunitinib, eight patients were using panitumumab, and six patients were using pertuzumab...In seven patients who developed acneiform side effects, systemic doxycycline was used, and in others, topical tetracycline and clindamycin were used...To treat these side effects, emollients, topical steroids, and local, systemic antibiotics are recommended. Clindamycin may be preferred as a topical treatment, and doxycycline may be preferred as a systematic treatment.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Herceptin (trastuzumab) / Roche
Journal: Divinylsulfonamides enable the construction of homogeneous antibody-drug conjugates. (Pubmed Central) - Jun 24, 2021
The conjugates demonstrated high efficacy and selectivity for killing target-positive cancer cells in vitro. The EGFR-targeted conjugates also showed significant antitumor activities in vivo.
- ||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
Concentrating of FAS rearrangement , maybe continuing BRAF inhibition with cetuximab add on to block EGF ligand binding activation of FAS pathway. Would encorafenib as a second generation inhibitor provide a better inhibiton ?? and last but not the least have you tried IO ? (Twitter) - Jun 24, 2021
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal: Clinical impact of weekly paclitaxel plus cetuximab is comparable to the EXTREME regimen for recurrent/metastatic head and neck squamous cell carcinoma. (Pubmed Central) - Jun 23, 2021
The EGFR-targeted conjugates also showed significant antitumor activities in vivo. wPTX-Cmab may be a suitable treatment option for R/M HNSCC patients with contraindications for platinum.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal: Analysis of skin dose distribution for the prediction of severe radiation dermatitis in head and neck squamous cell carcinoma patients treated with concurrent chemo-radiotherapy. (Pubmed Central) - Jun 22, 2021
wPTX-Cmab may be a suitable treatment option for R/M HNSCC patients with contraindications for platinum. Along with clinical factors, the pattern of dose distribution to a ring structure localized 2 mm below the patient's surface may help predict the development of severe RD.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, Journal: Evaluation of 18F-FDG PET/CT as an early imaging biomarker for response monitoring after radiochemotherapy using cetuximab in head and heck squamous cell carcinoma. (Pubmed Central) - Jun 22, 2021
P2
PET/CT2 has no prognostic value concerning PFS and cannot identify high risk patients for consolidation therapy. Imaging responders showed a significantly longer PFS compared to nonresponders and therefore PET/CT might serve as a prognostic biomarker.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Preclinical, Journal: A systematic comparison of label-free, SILAC and TMT techniques to study early adaption towards inhibition of EGFR signaling in the colorectal cancer cell line Difi. (Pubmed Central) - Jun 22, 2021
We analyzed the epidermal growth factor receptor (EGFR) signaling network, which plays an essential role in colorectal cancer, and studied its dynamics within 24 h upon treatment with the EGFR-blocking antibody cetuximab, representing the first cellular adaption toward therapy...These dynamics represented an initial downregulation of the MAPK pathway, which was partially rescued as soon as 24 h after treatment. We identified upregulation and signaling via ERBB3 as well as calcium and cAMP signaling as possible mechanisms bypassing the blockage of EGFR.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, P2 data, Journal: Methotrexate plus or minus cetuximab as first-line treatment in a recurrent or metastatic (R/M) squamous cell carcinoma population of the head and neck (SCCHN), unfit for cisplatin combination treatment, a phase Ib-randomized phase II study Commence. (Pubmed Central) - Jun 22, 2021
We identified upregulation and signaling via ERBB3 as well as calcium and cAMP signaling as possible mechanisms bypassing the blockage of EGFR. Cetuximab with methotrexate improved PFS without increased toxicity in R/M SCCHN-patients.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Retrospective data, Journal: Palliative chemotherapy with or without cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck: Indian tertiary care retrospective analysis. (Pubmed Central) - Jun 22, 2021
Cetuximab with methotrexate improved PFS without increased toxicity in R/M SCCHN-patients. Adding cetuximab to chemotherapy improved ORR, PFS, and OS in Indian R/M SCCHN patients, and cetuximab was well tolerated.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, P2 data, Journal: Paired phase II trials evaluating cetuximab and radiotherapy for low risk HPV associated oropharyngeal cancer and locoregionally advanced squamous cell carcinoma of the head and neck in patients not eligible for cisplatin. (Pubmed Central) - Jun 22, 2021
Among cisplatin ineligible patients, cetuximab treatment engendered poor outcomes. Rates of severe toxicities were on par with platinum-based regimens suggesting that cetuximab is not a benign treatment.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Preclinical, Journal: Image-based ex vivo drug screen to assess targeted therapies in recurrent thymoma. (Pubmed Central) - Jun 22, 2021
The results show that the image-based ex vivo therapy efficacy screening strategy can be used to identify patient and tumor relevant drug sensitivity patterns in thymoma. The results also warrant continued research on EGFR as a biomarker and therapy target in recurrent thymomas.
- | Keytruda (pembrolizumab) / Merck (MSD), Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal, HEOR: Quality of Life With Pembrolizumab for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: KEYNOTE-040. (Pubmed Central) - Jun 22, 2021
The results also warrant continued research on EGFR as a biomarker and therapy target in recurrent thymomas. GHS/QoL was stable with pembrolizumab but declined with SOC in patients at week 15, supporting the clinically meaningful benefit of pembrolizumab in R/M HNSCC.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal: Effects of postoperative adjuvant chemotherapy and palliative chemotherapy on the gut microbiome in colorectal cancer. (Pubmed Central) - Jun 22, 2021
GHS/QoL was stable with pembrolizumab but declined with SOC in patients at week 15, supporting the clinically meaningful benefit of pembrolizumab in R/M HNSCC. The community structure of gut bacteria and fungi changes in chemotherapy on CRCs.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: EGFR-targeted immunoliposomes efficiently deliver docetaxel to prostate cancer cells. (Pubmed Central) - Jun 22, 2021
Next, to increase the liposomes selectivity to prostate cancer cells, cetuximab, an anti-EGFR monoclonal antibody...As expected, our results showed higher cellular uptake and toxicity of immunoliposomes, compared to non-targeted liposomes, in DU145 (EGFR-overxpressing) prostate cancer cells. To the best of our knowledge, this is the first report of engineering EGFR-targeted liposomes to enhance the selectivity of DTX delivery to EGFR-positive prostate cancer cells.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Validation of an innovative analytical method for simultaneous quantification of alpha-cyano-4-hydroxycinnamic acid and the monoclonal antibody cetuximab using HPLC from PLGA-based nanoparticles. (Pubmed Central) - Jun 22, 2021
The developed method was also successfully used for the first time to quantify the CHC and CTX content in poly(lactic-co-glycolic acid)-based nanoparticles. In conclusion, this new and rapid method presented acceptable analytical performance and can be helpful to simultaneously quantify CHC and CTX in future studies applied to anticancer therapy.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Impact of blood-brain barrier permeabilization induced by ultrasound associated to microbubbles on the brain delivery and kinetics of cetuximab: An immunoPET study using Zr-cetuximab. (Pubmed Central) - Jun 22, 2021
FUS allowed significant and prolonged exposure to mAb in the brain parenchyma. This study confirms the potential of FUS as a target delivery method for mAb in CNS.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Review, Journal: Optimizing Treatment De-Escalation in Head and Neck Cancer: Current and Future Perspectives. (Pubmed Central) - Jun 22, 2021
Well-designed trials that optimize multimodal strategies are needed. Given the absence of positive randomized trials testing de-escalated therapy to date, practicing oncologists should exercise caution and administer established standard-of-care therapy outside the context of a clinical trial.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Weekly Cetuximab and Paclitaxel for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. (Pubmed Central) - Jun 22, 2021
Given the absence of positive randomized trials testing de-escalated therapy to date, practicing oncologists should exercise caution and administer established standard-of-care therapy outside the context of a clinical trial. Cmab-PTX may be considered as a treatment option in head and neck R/MHNSCC patients.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal, Real-world evidence: A real-world comparison of cisplatin vs cetuximab used concurrently with radiation in the treatment of locally advanced oropharyngeal carcinoma. (Pubmed Central) - Jun 22, 2021
Cmab-PTX may be considered as a treatment option in head and neck R/MHNSCC patients. Our data reaffirm results from randomized studies showing better survival outcomes with cis-RT compared to cetux-RT even among those who are >65 with CCI ≥3.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Review, Journal: EGFR targeting for cancer therapy: Pharmacology and immunoconjugates with drugs and nanoparticles. (Pubmed Central) - Jun 22, 2021
Finally, ADCs and ANCs state of the art will be reviewed and recent studies and clinical progresses will be highlighted. To the best of our knowledge, this is the first review paper to address specifically the EGFR target and its application on ADCs and ANCs.
- ||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, P3 data, Journal: Extended RAS Analysis of the Phase 3 EPIC Trial: Irinotecan + Cetuximab vs Irinotecan as Second-Line Treatment for Patients with Metastatic Colorectal Cancer. (Pubmed Central) - Jun 22, 2021
In this retrospective analysis of the phase 3 EPIC study (cetuximab plus irinotecan versus irinotecan alone as second-line treatment in patients with RAS-unselected mCRC), the subgroup of patients with RAS-wild-type mCRC who received cetuximab plus irinotecan had improved progression-free survival, objective response rate, and quality of life compared with the RAS-unselected population. These findings suggest that cetuximab-based therapy is a suitable second-line treatment for patients with RAS-wild-type mCRC.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical: Potentially Resectable mCRC-treated with Cetuximab Combined with Chemotherapy. (Pubmed Central) - Jun 22, 2021
Compared with patients receiving chemotherapy alone, the surgical resection rate and PFS are not increased in patients undergoing chemotherapy combined with cetuximab, but the OS is slightly prolonged. Key Words: Chemotherapy, Cetuximab, Colorectal cancer, Metastatic tumor, Surgery.